




RealRate

PHARMACEUTICAL 2018

Sonnet Biotherapeutics Holdings Inc
Rank 211 of 332



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Sonnet Biotherapeutics Holdings Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Sonnet Biotherapeutics Holdings Inc compared to the market average is the variable Other Revenues, increasing the Economic Capital Ratio by 71% points. The greatest weakness of Sonnet Biotherapeutics Holdings Inc is the variable Stockholders Equity, reducing the Economic Capital Ratio by 159% points.

The company's Economic Capital Ratio, given in the ranking table, is 209%, being 42% points below the market average of 252%.

Input Variable	Value in 1000 USD
Assets, Current	1,800
Cost of Goods Sold	0
Intangible Assets	18,545
Liabilities, Current	14,906
Liabilities, Non-Current	0
Other Assets	1,290
Other Compr. Net Income	592
Other Expenses	41,478
Other Liabilities	3,788
Other Net Income	-2,575
Other Revenues	41,433
Property and Equipment	8,549
Research and Development	0
Selling, General and Administrative Expense	4,545

Output Variable	Value in 1000 USD
Assets	30,183
Liabilities	18,694
Expenses	46,024
Revenues	41,433
Stockholders Equity	11,489
Net Income	-7,166
Comprehensive Net Income	-6,870
BaseVar	69,751
ECR before LimitedLiability	74%
Economic Capital Ratio	209%